Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven research firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average […]
HC Wainwright reaffirmed their buy rating on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research report report published on Wednesday, Benzinga reports. The firm currently has a $41.00 target price on the biopharmaceutical company’s stock. Several other equities analysts have also commented on RVNC. Needham & Company LLC lowered their price objective […]
Revance Therapeutics (NASDAQ:RVNC – Free Report) had its price target decreased by Needham & Company LLC from $40.00 to $35.00 in a report published on Wednesday, MarketBeat Ratings reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. Other research analysts have also recently issued research reports about the stock. […]
Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) – Investment analysts at William Blair reduced their Q3 2023 EPS estimates for shares of Revance Therapeutics in a research report issued to clients and investors on Wednesday, September 20th. William Blair analyst T. Lugo now forecasts that the biopharmaceutical company will earn ($1.43) per share for the […]
Baldwin Brothers LLC MA grew its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 300.0% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 2,000 shares of the biopharmaceutical company’s stock after acquiring an additional 1,500 shares during the quarter. Baldwin Brothers LLC […]